Assessment of Molecular Relapse Detection in Early-Stage Breast CancerIsaac García-Murillas, Nicholas C. Turner, Claire Swift et al.|JAMA Oncology|2019Cited by 425
Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancerNeha Chopra, Nicholas C. Turner|Nature Communications|2020Cited by 258
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i> - and Non– <i>BRCA1/2</i> -Mutant CancersTimothy A. Yap, Johann S. de Bono, Rebecca Kristeleit et al.|Cancer Discovery|2020Cited by 134